OVM-300

OVM-300 is a preclinical-stage recombinant overlapping peptide (ROP) vaccine being developed by Oxford Vacmedix for the treatment of benign prostatic hypertrophy (BPH). The vaccine utilizes the company's proprietary ROP platform, which involves the delivery of a single recombinant protein containing the full sequence of a target antigen as overlapping peptides. This design is intended to stimulate a comprehensive T-cell response (both CD4+ and CD8+) against prostate tissues involved in BPH without requiring HLA matching. While the specific molecular target for OVM-300 has not been publicly disclosed, the program aims to provide an immunotherapeutic approach to managing prostate enlargement by eliciting an immune response to relevant prostate antigens.